preview

Ptinue Continued Research

Decent Essays
The search for a new anti-migraine drug was started by Glaxo in 1972. In the 1960s, studies showed that vasoconstriction from 5-HT, ergotamine and nor-adrenaline could reduce migraine attacks. Research also showed that platelet 5-HT level reduces during migraine attacks. Many side-effects were associated with the use of 5-HT as a drug and then scientists started research on the receptors of 5-HT in order to discover and develop a more specific agonist for 5-HT receptors. Research on the 5-HT receptors and their effect led to discovery of several types and subtypes of 5-HT. AH24167 showed a vasodilatory effect instead of vasoconstrictory due to the agonist effect on another type of 5-HT receptors later assigned the name 5-HT7. AH25086 was the second compound developed and showed a vasoconstrictory effect but was not released as a drug due to low per oral bioavailability.…show more content…
Clinical trials with subcutaneous sumatriptan showed that 70–80 per cent of patients had reduced pain by one hour after treatment. Sumatriptan was launched in the subcutaneous formulation in 1991. In subsequent studies of oral sumatriptan 100mg–300mg, around 70 % of patients responded to treatment within two hours of administration and this led to the launch of 100mg sumatriptan tablets. Sumatriptan was first launched in the Netherlands in 1991 and became available in the USA during 1993. In year 2008, Treximet, a combination of sumatriptan and naproxen was approved by US-FDA for the treatment of migraine attacks. This combination has shown better efficacy in treating migraine attacks over other anti-migraine
Get Access